Therapy News and Research

RSS

USPTO issues patent to Positron’s solid state sensors

Positron Corporation announced today that the United States Patent and Trademark Office (USPTO) has awarded the Company a patent (U.S. No. 8,269,181) for its original semiconductor detector used in high precision measuring of coordinates and detection of ionization particles.

17 Oct 2012

VOICES of children with ADHD support medication use

Children with attention deficit/hyperactivity disorder benefit from the use of stimulant medication and do not feel that it turns them into “robots,” suggests research.

16 Oct 2012

Thrust techniques do not outweigh nonthrust for low-back pain

Early use of thrust manipulation does not offer improved outcomes and a quicker recovery from low-back pain compared with nonthrust techniques, US study findings suggest.

16 Oct 2012

Experts blaze TRAIL for pulmonary arterial hypertension therapy

Researchers have shown that the cell signaling molecule tumor necrosis factor-related apoptosis-inducing ligand may be a potential therapeutic target for pulmonary arterial hypertension.

16 Oct 2012

Widening treatment options for parotid duct stenoses

Parotidectomy should no longer be regarded as a routine treatment for parotid duct stenosis and should be indicated only in individual cases, report researchers.

16 Oct 2012

IMS develops review on weight gain at the menopause

To mark World Menopause Day (18th October) the International Menopause Society has developed a state-of-the-science review on weight gain at the menopause. This report is published in the peer-reviewed journal, Climacteric.

16 Oct 2012

Intensive treatment with high doses of statin drugs shows promise for dyslipidemia

A comprehensive new review on how to treat high cholesterol and other blood lipid problems suggests that intensive treatment with high doses of statin drugs is usually the best approach.

16 Oct 2012

Transcranial magnetic stimulation can benefit patients with depression, debilitating tinnitus

Three patients who have suffered periodic major depression throughout their adult lives told an audience attending a Loyola Grand Rounds presentation how their lives have been transformed by a new magnetic therapy.

16 Oct 2012

New radiation therapy can reduce risk of neurocognitive adverse effects in children

Children who undergo brain radiation therapy run a significant risk of suffering from permanent neurocognitive adverse effects. These adverse effects are due to the fact that the radiation often encounters healthy tissue. This reduces the formation of new cells, particularly in the hippocampus - the part of the brain involved in memory and learning.

16 Oct 2012

Animal research shows promise in treating AD, brain damage and heart problems resulting from SCIs

New animal studies provide additional support for investigating stem cell treatments for Parkinson's disease, head trauma, and dangerous heart problems that accompany spinal cord injury, according to research findings released today.

16 Oct 2012

Direct link between fuel exposure and damage to genetic material

An experiment carried out on rodents exposed to fuel similar to that of the Prestige tanker oil spill - which took place nearly a decade ago - shows that inhalation of the fuel causes damage to genetic material. According to the study, led by the University of A Coru-a, the results could be used in relation to people who carry out the industrial cleaning of coasts.

16 Oct 2012

Drug-eluting balloon procedure can effectively treat peripheral artery disease

Use of balloon angioplasty and placement of stents to widen clogged arteries have become standard medical procedure. Further advancing this treatment, drug-eluting devices are now delivering medication directly to the site where it can be most effective. While this technique has met with success in coronary arteries, its use in peripheral arteries is still under study.

16 Oct 2012

GAPPS announces five new projects for prevention of preterm births

Five innovative research projects aiming to prevent premature birth were announced today by the Global Alliance to Prevent Prematurity and Stillbirth (GAPPS), an initiative of Seattle Children's.

16 Oct 2012

Radioactive gold nanoparticle treatment safe and effective in dogs with prostate cancer

Currently, large doses of chemotherapy are required when treating certain forms of cancer, resulting in toxic side effects. The chemicals enter the body and work to destroy or shrink the tumor, but also harm vital organs and drastically affect bodily functions. Now, scientists at the University of Missouri have proven that a new form of prostate cancer treatment that uses radioactive gold nanoparticles, and was developed at MU, is safe to use in dogs.

16 Oct 2012

VeriStrat identifies NSCLC patients likely to respond to erlotinib

A study, published in the November 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, showed the plasma test VeriStrat can predict response but not survival benefit from erlotinib. The study was conducted on a subset of patients enrolled in the NCIC Clinical Trials Group, BR.21 phase III trial of erlotinib versus placebo in previously treated advanced non-small cell lung cancer patients.

16 Oct 2012

Fit elderly NSCLC patients should be considered for salvage targeted therapy

Until there are more validated biomarkers to direct treatment decisions, many physicians use patient age to decide what therapy to give their patients. Literature data report that older patients often go undertreated because of concerns for limited tolerance to toxic therapies.

16 Oct 2012

GILZ protein encourages bone growth in mouse model

Georgia Health Sciences University researchers have developed a mouse that errs on the side of making bone rather than fat, which could eventually lead to better drugs to treat inflammatory diseases such as rheumatoid arthritis.

16 Oct 2012

NIH to accelerate development and application of single cell analysis across various fields

The National Institutes of Health plans to invest more than $90 million over five years, contingent upon the availability of funds, to accelerate the development and application of single cell analysis across a variety of fields.

16 Oct 2012

New findings on Alzheimer's disease presented at Neuroscience 2012

Curtailing the imminent rise in Alzheimer's disease (AD) will require early, accurate diagnostic tests and treatments, and researchers are closer to achieving these two goals. New findings in medical imaging, molecular analysis of neurological diseases, and development of treatments using mouse models were presented at Neuroscience 2012, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news about brain science and health.

15 Oct 2012

Civitas to present CVT-301 Phase 1 study results at Parkinson's Disease Therapeutics Conference

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUS respiratory delivery platform, announced today that the Company will make its first public presentation at the Sixth Annual Parkinson's Disease Therapeutics Conference, sponsored by The Michael J. Fox Foundation for Parkinson's Research, to be held on October 24th in New York City.

15 Oct 2012